Emerald Medical Applications Corp. (OTCMKTS:MRLA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

0

Emerald Medical Applications Corp. (OTCMKTS:MRLA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January. 16, 2018, the Board of Directors of Emerald Medical Applications Corp. (the “Registrant”) received letters of resignation from Mrs. Estery Giloz-Ran and Mr. Ascher Shmulewitz, both members of the Registrant’s Board of Directors, resigning their positions as directors of the Registrant, effective January 18, 2018. Copies of the letters of resignation are attached as Exhibits 17.8 and 17.9 hereto.

Both letters of resignation stated that the respective directors had no disagreements with the operations, policies or practices of the Registrant on any matters.

On January 19, 2018, the Registrant’s Board of Directors appointed Mr. Eyal Ben-Ami as a member of the Board. Eyal Ben-Ami, age 41, Director: From 2008 to the present, Mr. Ben-Ami has served as the Director of Employee Benefits at the IDB Bank of Israel, founded in 1935 and one of Israel’s three largest banks. IDB Bank has more than 260 branches, a staff of approximately 5,700, assets of approximately US$50 billion and international operations with branches in Israel and the United States. From 1993 through 2007, Mr. Ben-Ami was a professional soccer player and a member of Hapoel Tel-Aviv FC, a professional Israeli soccer team, and a member of Israel’s National Soccer Team.

Item 8.01 Other Events.

The Registrant disclosed in its Form 10-Q for the period-ended September 30, 2017, under Note 8-Restatement, that it intended to file an amendment to the Form 10-K for the year-ended December 31, 2016 to restate its financial statements, as reflected under Note 8. The Registrant has determined that it is not required to file an amendment to the subject Form 10-K.

The Registrant also disclosed in its Form 10-Q for the period-ended September 30, 2017, under Note 9-Subsequent Events, that it was considering the advisability of establishing another wholly-owned Israeli subsidiary engaging in operations that should be more readily able to generate revenues and positive cash flow from operations than the Company’s existing subsidiary, Emerald Medical Applications Ltd. On January 1, 2018, the Registrant formed Virtual Crypto Technologies Ltd as a new wholly-owned subsidiary under the laws of the State of Israel, company ID #515778975 (Israeli equivalent of EIN) and has agreed to the appointment of Mr. Alon Dayan as CEO of the new subsidiary.

Item 9.01 Financial Statements and Exhibits.

(a) The following documents are filed as exhibits to this report on Form 8-K or incorporated by reference herein. Any document incorporated by reference is identified by a parenthetical reference to the SEC filing that included such document.


Emerald Medical Applications Corp. Exhibit
EX-17.8 2 ex17-8.htm   EXHIBIT 17.8   Letter of Resignation   Dated: January 16,…
To view the full exhibit click here

About Emerald Medical Applications Corp. (OTCMKTS:MRLA)

Emerald Medical Applications Corp. operates through its subsidiary, Emerald Medical Applications Ltd. (Emerald), which is a digital health company. Emerald is engaged in the development, sale and service of imaging solutions utilizing its DermaCompare software that it developed for use in derma imaging and analytics. Emerald’s DermaCompare solution allows dermatologists and other medical care professionals, using a set of total body photography (TBP), to capture sets of skin lesion images with, among other devices, digital cameras, camera-equipped smartphones or tablets. DermaCompare imaging solution is provided as a software platform for early detection of Melanoma for classification of dermatological lesions as published by the National Institute of Health (NIH) for analysis of moles. DermaCompare imaging software solution reads and extracts data from those images and in essence turns digital camera, camera-equipped smartphones and tablets into virtual scanning devices.